Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2094 USD | +16.98% | -40.41% | -63.58% |
May. 20 | Top Midday Decliners | MT |
May. 20 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of NVIDIA Earnings due Wednesday | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 5.81M |
---|---|---|---|---|---|
Net income 2024 * | -5M | Net income 2025 * | -8M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.95
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.26% |
Latest transcript on Virios Therapeutics, Inc.
1 day | +16.98% | ||
1 week | -40.41% | ||
Current month | -53.67% | ||
1 month | -50.75% | ||
3 months | -36.49% | ||
6 months | -65.56% | ||
Current year | -63.58% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Duncan
CEO | Chief Executive Officer | 59 | 17-12-31 |
Angela Walsh
DFI | Director of Finance/CFO | 58 | 20-03-31 |
Ralph Grosswald
COO | Chief Operating Officer | 55 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Thomas
BRD | Director/Board Member | 70 | 20-12-20 |
Richard Whitley
BRD | Director/Board Member | 78 | 20-12-20 |
Gregory Duncan
CEO | Chief Executive Officer | 59 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 0.2094 | +16.98% | 2,456,683 |
24-05-23 | 0.179 | -12.08% | 2,276,631 |
24-05-22 | 0.2036 | +10.83% | 963,175 |
24-05-21 | 0.1837 | -6.75% | 902,232 |
24-05-20 | 0.197 | -43.94% | 5,498,840 |
Delayed Quote Nasdaq, May 24, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.58% | 5.81M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- VIRI Stock